Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An updated series

被引：0
|
作者：
Shih, K. K. [1 ]
Chi, D. S. [1 ]
Barakat, R. R. [1 ]
Leitao, M. M. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA
来源：
GYNECOLOGIC ONCOLOGY | 2009年 / 112卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
306
引用
收藏
页码：S155 / S155
页数：1
相关论文
共 50 条
  • [31] Bevacizumab Combination Therapy: A Review of its Use in Patients with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    Sohita Dhillon
    BioDrugs, 2013, 27 : 375 - 392
  • [32] Bevacizumab Combination Therapy: A Review of its Use in Patients with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    Dhillon, Sohita
    BIODRUGS, 2013, 27 (04) : 375 - 392
  • [33] Surgical treatment of primary ovarian fallopian tube and peritoneal cancer
    Lindemann, Kristina
    Halaska, Michael J.
    Zalewski, Kamil
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 5 - 8
  • [34] Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer
    Backes, Floor J.
    Wei, Lai
    Chen, Min
    Hill, Kasey
    Dzwigalski, Kyle
    Poi, Ming
    Phelps, Mitch
    Salani, Ritu
    Copeland, Larry J.
    Fowler, Jeffrey M.
    Cohn, David E.
    Bixel, Kristin
    Cosgrove, Casey
    Hays, John
    O'Malley, David
    GYNECOLOGIC ONCOLOGY, 2021, 162 (03) : 619 - 625
  • [35] Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis
    Manning-Geist, Beryl L.
    Chi, Dennis S.
    Roche, Kara Long
    Zivanovic, Oliver
    Sonoda, Yukio
    Gardner, Ginger J.
    O'Cearbhaill, Roisin E.
    Abu-Rustum, Nadeem R.
    Leitao, Mario M., Jr.
    GYNECOLOGIC ONCOLOGY, 2021, 162 (02) : 345 - 352
  • [36] Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal cancer
    Backes, F. J.
    Wei, L.
    Cohn, D. E.
    Salani, R.
    Hays, J. L.
    Fowler, J. M.
    Copeland, L. J.
    O'Malley, D. M.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 23 - 23
  • [37] Safety and Outcome of Patients Treated with a Modified Outpatient Intraperitoneal Regimen for Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
    Battelli, Chiara
    Campo, Meghan
    Buss, Mary K.
    Awtrey, Christopher S.
    Konstantinopoulos, Panagiotis A.
    CHEMOTHERAPY, 2013, 59 (04) : 251 - 259
  • [38] Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes
    Pecorelli, S.
    Ray-Coquard, I.
    Tredan, O.
    Colombo, N.
    Parma, G.
    Tisi, G.
    Katsaros, D.
    Lhomme, C.
    Lissoni, A. A.
    Vermorken, J. B.
    du Bois, A.
    Poveda, A.
    Frigerio, L.
    Barbieri, P.
    Carminati, P.
    Brienza, S.
    Guastalla, J. P.
    ANNALS OF ONCOLOGY, 2010, 21 (04) : 759 - 765
  • [39] Tertiary cytoreduction in the setting of recurrent ovarian cancer
    Dogan, Nasuh Utku
    Schneider, Achim
    Chiantera, Vito
    Dogan, Selen
    Dursun, Polat
    ONCOLOGY LETTERS, 2013, 6 (03) : 642 - 647
  • [40] Celiac lymph node resection and porta hepatis disease resection in advanced or recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer
    Martinez, A.
    Pomel, C.
    Mery, E.
    Querleu, D.
    Gladieff, L.
    Ferron, G.
    GYNECOLOGIC ONCOLOGY, 2011, 121 (02) : 258 - 263
12345